Aditi Jhaveri

Employment

• Repertoire immune medicines Principal Scientist
  2021 - Present
• Northeastern University PhD Candidate
  2011 - 2017

Education

• Northeastern University PhD
  2011 - 2017
• Northeastern University MS

Projects & Funding

Projects & funding information is unavailable.

Publications (22)

• Tolerogenic nanoliposomes for the treatment of Rheumatoid Arthritis
  The Journal of Immunology 2020 DOI: 10.4049/jimmunol.204.supp.237.2
  +Save
• Tolerogenic nanoparticles suppress central nervous system inflammation
  Proceedings of the National Academy of Sciences 2020 DOI: 10.1073/pnas.2016451117
  +Save
• The Aryl Hydrocarbon Receptor as a regulator of CNS autoimmunity
  The Journal of Immunology 2019 DOI: 10.4049/jimmunol.202.supp.193.13
  +Save
• Advancing methods for the analysis of glioblastoma cell motion using quantitative time lapse holographic imaging and cellular tomography
  Progress in Biomedical Optics and Imaging - Proceedings of SPIE 2019 DOI: 10.1117/12.2510236
  +Save
• The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells
  Journal of Drug Targeting 2018 DOI: 10.1080/1061186x.2018.1550647
  +Save
• Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer
  Drug Delivery 2018 DOI: 10.1080/10717544.2018.1435747
  +Save
• Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
  Journal of Controlled Release 2018 DOI: 10.1016/j.jconrel.2018.03.006
  +Save
• PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity
  Acta Biomaterialia 2017 DOI: 10.1016/j.actbio.2017.04.008
  +Save
• Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG
  International Journal of Pharmaceutics 2017 DOI: 10.1016/j.ijpharm.2017.08.095
  +Save
• Combination Nanopreparations of a Novel Proapoptotic Drug – NCL-240, TRAIL and siRNA
  Pharmaceutical Research 2016 DOI: 10.1007/s11095-016-1899-z
  +Save